Table 2 Clinical outcomes during the follow-up period
From: Prevalence and impact of fibrinolytic dysregulation in patients with acute coronary syndromes
Events | Total N = 338 | Fibrinolysis | P value | ||
|---|---|---|---|---|---|
Physiologic N = 99 | Shutdown N = 163 | Hyper- N = 76 | |||
MACEsa | 77 (22.8) | 19 (19.2) | 33 (20.2) | 25 (32.9) | 0.057 |
All-cause death | 17 (5.0) | 4 (4.0) | 10 (6.3) | 3 (3.9) | 0.668 |
ACS | 35 (10.4) | 9 (9.1) | 14 (8.6) | 12 (15.8) | 0.208 |
Stroke/TIA | 26 (7.7) | 3 (3.0) | 13 (8.0) | 10 (13.2) | 0.044 |
Heart failure | 24 (7.1) | 4 (4.0) | 11 (6.7) | 9 (11.8) | 0.134 |
Bleeding | 9 (2.7) | 4 (4.0) | 4 (2.5) | 1 (1.3) | 0.540 |